The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs — the most ever for the ...

And, if all goes well, over the next five years as well.

Carvykti sales surge, MRD FDA guidance speeds label expansion, and strong cash runway. Click for more on LEGN stock.

Lower interest rates aided the biotech bounceback, as many companies in the sector rely on a big dose of debt. Their shares ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and ...

At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best set yourself up for success, adapt your approach to the specific scientific ...

Stay updated on biotech layoffs in 2026! Each week, we track and analyze industry layoffs, their causes, and their impact.